The immuno-oncology drug developer, backed by several pharmaceutical firms, has raised $55m in an IPO that saw it float substantially below its $14 to $16 range.
Merus, a Netherlands-based immuno-oncology treatment developer backed by pharmaceutical companies Novo, Novartis, Johnson & Johnson and Pfizer, raised $55m on Thursday in an initial public offering in the US.
The company issued 5.5 million shares priced at $10 each, below the $14 to $16 range it set earlier this month, though it upped the number of shares in the offering from 4.3 million. It initially filed to raise up to $60m in October 2015.
Merus is working on antibody therapeutics…
